In this episode of "The Top Line," Fierce Biotech's Annalee Armstrong engages in a conversation with Howard Fillit, M.D., an expert in the field of Alzheimer's research and the co-founder and chief science officer at the Alzheimer's Drug Discovery Foundation.

They delve into the pioneering work being done in Alzheimer's research, discuss the latest breakthroughs, and explore the ongoing efforts to combat this complex disease.

To learn more about the topics in this episode: 


With full Alzheimer's approval in hand, Eisai and Biogen kick off Leqembi's launch in earnest


Eisai, Biogen's Leqembi may face rollout hurdles now, but experts still like the Alzheimer's drug


Experimental Alzheimer's molecule improves cognition in mice by tamping down on inflammation


Voyager Therapeutics adds anti-amyloid gene therapy to Alzheimer's pipeline


Acumen's stock surges as early Alzheimer's data suggest next-gen Leqembi rival is active

In this episode of "The Top Line," Fierce Biotech's Annalee Armstrong engages in a conversation with Howard Fillit, M.D., an expert in the field of Alzheimer's research and the co-founder and chief science officer at the Alzheimer's Drug Discovery Foundation.
They delve into the pioneering work being done in Alzheimer's research, discuss the latest breakthroughs, and explore the ongoing efforts to combat this complex disease.
To learn more about the topics in this episode: 
<ul>
<li>
<a href="https://www.fiercepharma.com/pharma/full-approval-hand-eisai-and-biogen-kick-leqembis-alzheimers-launch-earnest" data-cke-saved-href="https://www.fiercepharma.com/pharma/full-approval-hand-eisai-and-biogen-kick-leqembis-alzheimers-launch-earnest">With full Alzheimer's approval in hand, Eisai and Biogen kick off Leqembi's launch in earnest</a>
</li>
<li>
<a href="https://www.fiercepharma.com/pharma/eisai-biogens-leqembi-may-face-rollout-hurdles-now-experts-still-alzheimers-drug" data-cke-saved-href="https://www.fiercepharma.com/pharma/eisai-biogens-leqembi-may-face-rollout-hurdles-now-experts-still-alzheimers-drug">Eisai, Biogen's Leqembi may face rollout hurdles now, but experts still like the Alzheimer's drug</a>
</li>
<li>
<a href="https://www.fiercebiotech.com/research/alzheimers-drug-improves-cognition-mice-tamping-down-inflammation" data-cke-saved-href="https://www.fiercebiotech.com/research/alzheimers-drug-improves-cognition-mice-tamping-down-inflammation">Experimental Alzheimer's molecule improves cognition in mice by tamping down on inflammation</a>
</li>
<li>
<a href="https://www.fiercebiotech.com/research/voyager-therapeutics-adds-anti-amyloid-gene-therapy-alzheimers-pipeline" data-cke-saved-href="https://www.fiercebiotech.com/research/voyager-therapeutics-adds-anti-amyloid-gene-therapy-alzheimers-pipeline">Voyager Therapeutics adds anti-amyloid gene therapy to Alzheimer's pipeline</a>
</li>
<li>
<a href="https://www.fiercebiotech.com/biotech/acumen-surges-early-alzheimers-data-suggest-next-gen-leqembi-rival-active" data-cke-saved-href="https://www.fiercebiotech.com/biotech/acumen-surges-early-alzheimers-data-suggest-next-gen-leqembi-rival-active">Acumen's stock surges as early Alzheimer's data suggest next-gen Leqembi rival is active</a>
</li>
</ul>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Advertisement